Short-term observation of direct oral anticoagulant use in an atrial fibrillation patient with high bleeding risk and kidney transplant:a case report
Wei XIANG1
Ling-Yun KONG1
Jing BAI1
Jun-Jie XIE2
Fang LIU1
1.Department of Cardiology,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing,China2.Department of Organ Transplant Center,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing,China
摘要：K idney transplant (KTx) is considered to be the best treatment for end-stage renal diseases compared with hemodialysis or peritoneal dialysis,because it significantly im-proves renal function,reduces cardiovascular events and mortality,enhances quality of life and pro-longs life expectancy.[1,2] Atrial fibrillation (AF) is frequently coexistent with KTx,and a higher risk will occur in KTx recipients with AF compared with those aren't with AF.[3] Patients with AF are at risk of stroke,systemic emboli and death.It is recom-mended that high-risk AF patients should use oral anticoagulants for preventive treatment.Direct oral anticoagulants (DOACs),including dabigatran,rivaroxaban,apixaban and edoxaban,are widely recommended for use in the general population compared to vitamin K antagonists (VKA).[4,5]However,in the chronic kidney disease population,the evidence for the use of DOACs is limited because all these drugs are partially eliminated by the kidney and may cause subsequent accumulation and bleed-ing risks.[6] To date,clinical evidence regarding the use of DOACs in KTx recipients is scarce.Herein,we report a successful case of the use of DOACs for an AF patient with high bleeding risk and a history of KTx several months ago and the short-term follow-up shows that its safety is good.
机标关键词：
论文发表日期：2021-08-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：5( 692-696 )